Fact based stock research
Realcan Pharmaceutical (SZSE:002589)

Realcan Pharmaceutical stock research in summary

Realcan Pharmaceutical shares have a market-typical stock price level. They are safely financed, are good value and show above average growth. We recommend evaluating whether the future of the company Realcan Pharmaceutical is typical for this industry which the market average price level of the shares suggests. If you believe that the future of the company is above average, that could be an argument for buying the shares and vice versa.

Latest Obermatt Ranks


Value Rank	61
Growth Rank	55
Safety Rank	100
Combined Rank	95

Country	China
Industry	Health Care Distributors
Index
Size class	X-Large

October 4, 2019. Stock data may be delayed. Login to get the most recent research.

Add to Watchlist

Filter Similar Stocks

Similar Top 10

Google: Realcan Pharmaceutical

News	Videos
Wikipedia about Realcan Pharmaceutical	Management
Employee Satisfaction	Customer Satisfaction

Research History: Realcan Pharmaceutical

RESEARCH HISTORY	2016	2017	2018	2019
VALUE
VALUE	32	32	75	61
GROWTH
GROWTH	67	100	82	55
SAFETY
SAFETY	100	100	48	100
COMBINED
COMBINED	83	83	82	95

Last update of Combined Rank: 4-Oct-2019. Financial reporting date used for calculating ranks: 30-Jun-2019. Stock research history is based on the Obermatt Method. The higher the rank, the better Realcan Pharmaceutical is in the corresponding investment strategy.

Value Metrics in Detail

VALUE METRICS	2016	2017	2018	2019
PRICE VS. REVENUES (P/S)
PRICE VS. REVENUES (P/S)	68	68	81	87
PRICE VS. PROFITS (P/E)
PRICE VS. PROFITS (P/E)	29	29	88	60
PRICE VS. CAPITAL (Market-to-Book)
PRICE VS. CAPITAL (Market-to-Book)	30	40	82	74
DIVIDEND YIELD
DIVIDEND YIELD	22	22	28	26
CONSOLIDATED RANK: VALUE
CONSOLIDATED RANK: VALUE	32	32	75	61

Last update of Value Rank: 4-Oct-2019. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Realcan Pharmaceutical; except for dividend yield where the rank is higher, the higher the yield.

Growth Metrics in Detail

GROWTH METRICS	2016	2017	2018	2019
REVENUE GROWTH
REVENUE GROWTH	96	89	96	84
PROFIT GROWTH
PROFIT GROWTH	87	87	89	52
STOCK RETURNS
STOCK RETURNS	30	52	32	4
CONSOLIDATED RANK: GROWTH
CONSOLIDATED RANK: GROWTH	67	100	82	55

Last update of Growth Rank: 30-Jun-2019. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Realcan Pharmaceutical.

Safety Metrics in Detail

SAFETY METRICS	2016	2017	2018	2019
LEVERAGE
LEVERAGE	62	44	6	40
REFINANCING
REFINANCING	90	90	96	98
LIQUIDITY
LIQUIDITY	100	40	45	87
CONSOLIDATED RANK: SAFETY
CONSOLIDATED RANK: SAFETY	100	100	48	100

Last update of Safety Rank: 27-Sep-2019. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Realcan Pharmaceutical and the more cash is available to service its debt.

Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Realcan Pharmaceutical from October 4, 2019.

We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.